Malabsorption, sometimes called a malabsorption syndrome, is a problem where the body cannot properly take in nutrients from food. This can happen for many reasons, such as issues with the small intestine, problems after certain surgeries, or conditi...
Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
The FARE Patient Registry is a prospective observational study focused on collecting detailed health and basic information about individuals living with food allergies. Its purpose is to encourage open sharing of de-identified data and to support participation in clinical trials, ultimately aiming to advance scientific discoveries related to food allergy causes and contributing factors. This registry does not involve any treatment or interventions but gathers real-world experiences from participants with food allergies. It serves as a platform for the food allergy community to contribute data that can help researchers understand the extent and etiology of food allergies. Participants provide their health information and experiences, which are stored in the registry for ongoing research use. The main outcome measured is the creation of a registry that characterizes food allergies and factors influencing their development. The study is observational, with no interventions, and participation can continue until the study end date in August 2027.
Actively Recruiting
Researchers are investigating whether the thickness of gastrostomy tubes affects the rate of postoperative complications in children who need long-term enteral nutrition. This study compares two tube sizes, 12 Fr and 14 Fr, to see if a smaller tube might reduce issues such as granuloma, infection, pain, dislocation, and leakage. Gastrostomy is a common procedure in children with conditions like neurological diseases and metabolic disorders, and the study aims to provide clearer guidance on tube size choice. Children scheduled for laparoscopic gastrostomy are randomly assigned to receive either a 12 Fr or 14 Fr gastrostomy tube. After surgery, the tubes are changed at three months following national guidelines. Both families and healthcare personnel complete questionnaires about any complications experienced during this period. The data collected will be analyzed to determine if tube size influences complication rates. Participants will have a gastrostomy placed and then return for a follow-up visit three months later when the tube is changed. During this visit, questionnaires about complications such as granuloma formation, infection, pain, dislocation, and leakage will be completed by nurses and caregivers. The study will collect and analyze this information to assess outcomes. Participation involves surgery, follow-up care, and data collection over a three-month postoperative period.
Actively Recruiting
Researchers are evaluating the effect of lactase enzyme supplements in preventing feeding intolerance among preterm newborns in a neonatal intensive care unit. The study focuses on preterm neonates born at or before 32 weeks gestational age who start feeding within the first 72 hours of life. This research is important to understand how lactase enzyme may support feeding in these vulnerable infants. Participants will be randomly assigned to receive either lactase enzyme drops added to their formula milk or a placebo with no lactase. The lactase group will receive one drop per 10 ml of formula for 14 days. The control group will receive 10 ml of milk without lactase. The study includes a 14-day treatment period starting shortly after feeding begins. During the study, researchers will monitor feeding intolerance during the first two weeks of life. Assessments will include careful observation of feeding tolerance, clinical status, and any complications. The study will follow infants closely with routine evaluations to measure the main outcome related to feeding tolerance. The total duration of participation aligns with the initial two weeks of feeding after birth.
Actively Recruiting
Candy cane syndrome CCS is a complication that can happen after stomach surgery like gastrectomy or gastric bypass, where a part of the intestine enlarges and causes symptoms such as pain, nausea, vomiting, fullness, reflux, weight loss, and difficulty eating. This syndrome is mainly mechanical and can lead to serious problems like cachexia. Researchers are evaluating a new medical device called MAGUS to treat CCS in a less invasive way compared to the current surgical option, which can have significant risks and only moderate success. This study aims to assess the safety and effectiveness of this device in patients with CCS. The treatment involves placing the MAGUS device inside the digestive tract using an endoscopic procedure under general anesthesia with fluoroscopic guidance. The device works by using magnets to create pressure necrosis and open the blind loop within about 30 days. This study will enroll 51 patients at a single center, and the device placement will be carefully monitored with imaging before and after the procedure. Follow-up visits will occur at 14 days, 28 days, 3 months, and 12 months after treatment. Participants will undergo physical exams, medical history reviews, symptom scoring, and quality of life questionnaires both before and after the device placement. Imaging tests such as barium swallow X-rays or endoscopic assessments will be used to evaluate the blind loop. Researchers will track safety by monitoring adverse events throughout the study and assess how symptoms change over time. The study will last up to 12 months post-procedure, with a 3-year enrollment period, to fully understand the devices performance and patient satisfaction.
Actively Recruiting
Researchers are studying adults with lactase non-persistence LNP, a genetic condition that causes lactose intolerance due to low lactase enzyme levels. This trial aims to evaluate the effects of drinking lactose-containing versus lactose-free milk on gut bacteria and blood sugar control in people with pre-diabetes who normally consume at least one cup of milk daily. The study is based on findings suggesting milk intake may reduce type 2 diabetes risk in LNP individuals by altering gut microbiota and related metabolites. The study begins with a 2-week milk washout period, after which participants are randomly assigned to drink either lactose-containing 1% or 2% or lactose-free 1% or 2% milk for 12 weeks. Milk intake increases in stages half a cup daily for weeks 1-4, one cup daily for weeks 5-8, then two cups daily for weeks 9-12. After the main study period, participants continue drinking two cups daily for an additional two weeks. Participants will have visits before and after the 12-week milk intervention, with tests including lactose challenge hydrogen breath tests and blood draws for glucose, hemoglobin A1c, and metabolomics. Stool samples and continuous glucose monitoring data will be collected at home. The study will assess changes in gastrointestinal symptoms, gut microbiome characteristics, and various measures of blood sugar control throughout the 12 to 14 weeks of participation.
Actively Recruiting
Lactose intolerance LI happens when the body cannot properly digest lactose, causing symptoms like abdominal pain, cramps, gas, and diarrhea. This condition often overlaps with irritable bowel syndrome IBS, which causes abdominal pain and changes in bowel habits. This study looks at whether a lactose breath test can predict how well people with moderate to severe IBS respond to a lactose-free diet and aims to see if this diet improves quality of life in these patients. Participants will be grouped based on their lactose breath test results into H2BT-positive or H2BT-negative categories. Both groups will receive guidance from a trained dietitian on following a lactose-free diet. The study focuses on evaluating the diets effect over a short term and longer term, with careful monitoring of symptoms and quality of life changes. During the study, participants IBS symptoms and severity will be assessed using standardized scales at several visits, including at week 4. Researchers will track symptom improvement and changes in IBS severity scores. The study includes close monitoring for safety and adherence to the diet, with a total participation age range of 18 to 75 years. The study began in 2021 and will continue until 2028.
Actively Recruiting
This research aims to understand how much the Italian population knows about lactose intolerance, which is caused by lactose malabsorption. It considers different types of lactase deficiency, including primary, secondary, congenital, and developmental causes. The goal is to improve knowledge about clinical features, diagnosis, and treatment of lactose intolerance to help people manage the condition better. Participants are asked to complete an anonymous online survey designed to represent the Italian population. The survey collects information about peoples awareness of lactose intolerance and related issues. This observational study does not involve treatments but focuses on gathering data through the survey. During the study, participants will complete the online survey about their knowledge of lactose intolerance. Researchers will evaluate the survey responses over three months. The findings will be shared through a publication aimed at both people with lactose intolerance and nutritionists, including helpful tables and flow charts to support better diagnosis and management. The study participation involves completing the survey only.
Actively Recruiting
Researchers are conducting an international patient registry called the Coordination of Rare Diseases at Sanford CoRDS for individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence. This registry supports research by collecting health information and facilitating natural history studies, participant recruitment, and other research efforts to advance knowledge across more than 7,000 rare diseases. Participants include individuals with rare diseases, family members, caregivers, and carriers who voluntarily contribute demographic, contact, family history, and health data. Through partnerships with patient advocacy groups and researchers worldwide, CoRDS connects rare disease communities with research opportunities and shares data with qualified researchers after appropriate review, all at no cost to participants or researchers. Participants provide information periodically to maintain current data and support ongoing research. The registry may contact participants about relevant research opportunities and shares select information with advocacy organizations with consent. The main goal is to accelerate research into rare disorders by linking interested individuals with researchers over a long-term period, and participation is voluntary and free of charge.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of crofelemer in adults with Short Bowel Syndrome and Intestinal Failure SBS-IF who do not have colon-in-continuity and require parenteral support. This randomized, placebo-controlled, double-blind Phase 2 study aims to compare two doses of crofelemer with a placebo over a 24-week period. The study includes patients who are dependent on parenteral support and have chronic non-infectious diarrhea. Participants will be randomized to receive either crofelemer 3 mgkgdose, crofelemer 10 mgkgdose, or a matching placebo. The study drug is given orally or enterally three times daily morning, midday, and evening for 24 weeks. Before starting treatment, patients undergo up to a 4-week screening period followed by a parenteral support stabilization period lasting 2 to 12 weeks. After the 24-week treatment period, there will be a 4-week safety follow-up. During the study, participants will have visits at baseline and at weeks 1, 2, 4, 8, 12, 16, 20, and 24. Researchers will monitor safety, tolerability, and preliminary efficacy by assessing changes in parenteral support volume, stool characteristics, laboratory values, and physical exams. The study will measure outcomes related to parenteral support needs and stool consistency. After treatment, participants are followed for safety for 4 weeks. Total participation includes screening, stabilization, treatment, and follow-up periods.
Actively Recruiting
Researchers are examining whether patients with irritable bowel syndrome IBS who have a reduced ability to break down starch and sugar due to lower enzyme levels experience a smaller rise in blood glucose after a meal compared to those with normal enzyme levels. The study also aims to see if these patients have more bowel symptoms following the meal. This interventional study focuses on the relationship between enzyme function and blood sugar and symptom changes in IBS patients. Participants, all previously tested genetically for sucrase-isomaltase SI and other carbohydrate absorption enzymes, will complete lifestyle and symptom questionnaires at home before attending the clinic fasting. During the visit, a plastic tube is placed in the arm for blood sampling, and participants eat a sugar-rich meal over 15 minutes. Blood samples for glucose measurement are taken before, during, and at various times up to 2 hours after the meal, alongside symptom questionnaires. The study will compare the changes in blood glucose and bowel symptoms between those with reduced and normal enzyme activity. Researchers will analyze how blood sugar levels relate to symptoms. The total observation period for measuring outcomes after the meal is 2 hours, with symptom assessments done simultaneously. This study also collects detailed symptom scores using visual analog scales and IBS severity scoring systems.
1-10 of 12
1